title: Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.
abstract: Vaccinia infection interferes with the presentation of influenza Haemagglutinin (HA) and Nucleoprotein (NP) to class I-restricted CTL. The inhibitory effect is selective for certain epitopes, and is more profound during the late phase of infection. For influenza A/NT/60/68 NP, the block is present during both early and late phases of infection, and is selective for the COOH-terminal epitope defined by peptide 366-379, having no detectable effect on the presentation of the NH2-terminal epitope 50-63. The presentation of HA is inhibited only during the late phase of vaccinia infection. For both proteins, presentation is partially (NP) or completely (HA) restored by expression of rapidly degraded protein fragments in the vaccinia infected target cell. For HA, deletion of the NH2-terminal signal sequence completely overcomes the block. For NP, either a large NH2-terminal deletion or the construction of a rapidly degraded ubiquitin-NP fusion protein partially restores presentation. These results illustrate the relationship between degradation of viral proteins in the cytoplasm of an infected cell and recognition of epitopes at the cell surface by class I-restricted T cells.
authors: Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford.
authors: A
authors: A
authors: Townsend
authors: J
authors: J
authors: Bastin
authors: K
authors: K
authors: Gould
authors: G
authors: G
authors: Brownlee
authors: M
authors: M
authors: Andrew
authors: B
authors: B
authors: Coupar
authors: D
authors: D
authors: Boyle
authors: S
authors: S
authors: Chan
authors: G
authors: G
authors: Smith
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D000939:Epitopes / Q000276:immunology; D005260:Female; D005822:Genetic Vectors; D006389:Hemagglutinins, Viral / Q000235:genetics / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D009698:Nucleoproteins / Q000276:immunology; D009975:Orthomyxoviridae / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology; D011233:Precipitin Tests; D011401:Promoter Regions, Genetic; D021382:Protein Sorting Signals / Q000235:genetics / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*
chemical_list: D000939:Epitopes; D006389:Hemagglutinins, Viral; D015395:Histocompatibility Antigens Class I; D009698:Nucleoproteins; D010446:Peptide Fragments; D021382:Protein Sorting Signals; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins